Archaeal Glycerolipids Are Recognized by C-Type Lectin Receptor Mincle.


Journal

Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056

Informations de publication

Date de publication:
23 08 2023
Historique:
medline: 24 8 2023
pubmed: 9 8 2023
entrez: 9 8 2023
Statut: ppublish

Résumé

Recently, various metabolites derived from host microbes have been reported to modulate the immune system, with potential involvement in health or diseases. Archaea, prokaryotic organisms, are present in the human body, but their connection with the host is largely unknown when compared to other microorganisms such as bacteria. This study focused on unique glycerolipids from symbiotic methanogenic archaea and evaluated their activities toward an innate immune receptor. The results revealed that archaeal lipids were recognized by the C-type lectin receptor Mincle and induced immune responses. A concurrent structure-activity relationship study identified the key structural features of archaeal lipids required for recognition by Mincle. Subsequent gene expression profiling suggested qualitative differences between the symbiotic archaeal lipid and the pathogenic bacteria-derived lipid. These findings have broad implications for understanding the function of symbiotic archaea in host health and diseases.

Identifiants

pubmed: 37555666
doi: 10.1021/jacs.3c05473
doi:

Substances chimiques

Lectins, C-Type 0
Receptors, Immunologic 0
Lipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18538-18548

Auteurs

Shiori Oka (S)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Miyuki Watanabe (M)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka 565-0871, Japan.

Emi Ito (E)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka 565-0871, Japan.

Ami Takeyama (A)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka 565-0871, Japan.

Takuro Matsuoka (T)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Masatomo Takahashi (M)

Division of Metabolomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka 812-8582, Japan.

Yoshihiro Izumi (Y)

Division of Metabolomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka 812-8582, Japan.

Norihito Arichi (N)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Hiroaki Ohno (H)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Sho Yamasaki (S)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka 565-0871, Japan.

Shinsuke Inuki (S)

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH